CIDP Maintenance: A Delivery-Route Switch, or a Question About Steroid Responsiveness
A single patient, stable on maintenance IVIG but tired of the infusion-center schedule it demands. The disagreement isn't only about IVIG versus subcutaneous self-administration — it's about whether anyone has actually tested whether he needs immunoglobulin at all.
Every three weeks, W.B.'s dispatcher blocks off a route that can absorb a 90-minute detour to an infusion center — the logistics that have kept him working as a long-haul truck driver through the year since CIDP first took away his ability to grip a steering wheel reliably, weakness that showed up first as dropped coffee cups and a persistent numbness creeping up past his ankles. He is 58, and stabilizing on maintenance IVIG has been, so far, worth the price of that recurring detour. His INCAT disability score today sits at 1, near-normal strength on exam, and by any functional measure the current regimen is working. What's changed is not his disease but his patience for the logistics of it — missed dispatch windows, routes turned down because they'd conflict with an infusion date, a dispatcher who has started scheduling around him rather than the other way around, and a job that doesn't accommodate a fixed recurring appointment as easily as it once seemed to.
The PATH trial, published in 2018, tested exactly the alternative he's now asking about: switching stabilized CIDP patients from IVIG to subcutaneous immunoglobulin, self-administered at home. What PATH actually tested is narrower than the way it often gets described: it randomized IVIG-dependent patients to weekly subcutaneous immunoglobulin at one of two doses or to placebo — not to continued IVIG. Both SCIG doses significantly reduced relapse against placebo, which establishes subcutaneous dosing as effective maintenance therapy, but it is not a head-to-head demonstration that SCIG matches staying on IVIG. The trade he would be making is a recurring center visit for a weekly self-injection routine he'd need to learn and sustain on the road. What the trial doesn't answer is a question specific to W.B.: whether his CIDP, like a real minority of IVIG-responsive cases, might also respond to corticosteroids — a possibility nobody has actually tested in him, since his brief pre-diagnosis steroid course happened before CIDP was confirmed and its response was never clearly assessed.
A delivery-route switch, or a bigger question underneath it
I'd switch him to SCIG. PATH — van Schaik and colleagues, 2018 — is the largest randomized trial of maintenance therapy in CIDP, and both subcutaneous doses it tested significantly reduced relapse compared with placebo in IVIG-dependent patients, with fewer systemic infusion-related side effects. For a truck driver whose real complaint is the infusion-center schedule itself, trading that for a home self-injection routine directly addresses the problem he's describing, with trial-level evidence behind the switch, not just convenience reasoning.
I don't dispute PATH's result at the population level. My concern is narrower: W.B. is currently stable, and any treatment transition carries real risk of a relapse during the switch window, which PATH's own design managed carefully — it ran an IgG-dependency test period and an IVIG re-stabilization period before randomization, structure most real-world switches don't replicate. And I'd put the point more sharply than you did: PATH compared SCIG with placebo, not with staying on IVIG, so it tells us SCIG works — not that switching him off a regimen that is currently working costs him nothing. There's also a technique burden SCIG introduces that IVIG doesn't — weekly self-injection while managing a long-haul driving schedule is a different kind of logistic demand, not simply a smaller one, and it needs real training and support to actually work for him.
Before we lock in either delivery route indefinitely, I'd want to test something neither of you has raised: whether W.B.'s CIDP is corticosteroid-responsive. A real subset of IVIG-responsive CIDP patients also respond to steroids, and his own steroid exposure predates his confirmed diagnosis, so we genuinely don't know where he falls.
Framing this purely as IVIG-versus-SCIG treats route of administration as the only variable in play, when a supervised steroid taper, if he responds, could reduce or eliminate his dependence on immunoglobulin therapy in either form — a bigger answer to his actual complaint than switching which building the drug comes from. I'd propose a cautious, monitored steroid trial before committing to a long-term SCIG regimen.
Resolved for now: a monitored corticosteroid trial begins alongside continued IVIG, with a structured taper attempt over the following months. If steroid-responsive, immunoglobulin therapy may be reduced or stopped; if not, the SCIG switch remains the agreed next step.